Healthcare & Pharmaceuticals
🟢 SERP-Grounded (Light Telemetry)
Seagen
Programmatic AI Search & Model Visibility Audit
Share of Model (SOM)The percentage of time frontier AI models (ChatGPT, Claude, Gemini) recommend this brand for high-intent category queries.
0.3%
+0.0% 30-Day MomentumThe rolling 30-day change in algorithmic Share of Model. Positive momentum indicates increasing AI mindshare.
🧠 Neural Valency:DominantThe contextual sentiment of the AI's recommendation. 'Dominant' implies strong conviction, while 'Vulnerable' implies the model heavily conditions its recommendation.
Algorithmic Threat Detection
Primary Competitor Threat
Gilead Sciences
Competitor Displacement Rate
0.1%
Competitors are displacing Seagen in 0.1% of high-intent buyer queries.The frequency at which AI models actively suggest a competitor as a superior alternative to this brand.
Algorithmic Rationale: Seagen leads in antibody-drug conjugates (ADCs), but competition is intensifying with rivals developing similar or next-generation targeted therapies and expanding indications.
Missing AI Citations:High-authority domains (e.g., Reddit, G2) that models cite to justify recommending competitors, where this brand currently lacks presence.
[cancer.org][nejm.org]⚠️ Identified Vulnerability:ADC Pipeline
Primary Threat Identified:Gilead Sciences
Target Persona:Oncology Therapeutic Buyers
🚨 Threat Velocity:6/10An algorithmic urgency score (1-10) indicating how rapidly competitors are capturing this brand's historical AI search share.
Unlock Full Threat Report (30 Free Credits)